Defendant
1 case as defendant.
Lupin Pharmaceuticals, Inc. is the U.S. wholly-owned subsidiary of Lupin Limited, an Indian multinational pharmaceutical company. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. was incorporated in 2002 and commenced U.S. operations in 2003. The parent company, Lupin Limited, was founded in 1968 and is a public company listed on the Bombay Stock Exchange and National Stock Exchange in India. Lupin Pharmaceuticals, Inc. had an estimated annual revenue of $1.1 billion and approximately 5,709 employees.
The company is an operating pharmaceutical firm dedicated to delivering high-quality branded and generic medications across the United States. Its extensive product portfolio includes generics, complex generics, branded formulations, biosimilars, over-the-counter drugs, and active pharmaceutical ingredients (APIs). Lupin Pharmaceuticals, Inc. focuses on a wide range of therapeutic areas, including cardiovascular, diabetology, asthma, pediatrics, anti-infectives, women's health, and respiratory care. Notable products include Suprax (a pediatric antibiotic), Solosec (for bacterial vaginosis and trichomoniasis), and generic versions of drugs for conditions like COPD and type 2 diabetes.
In terms of patent litigation, Lupin Pharmaceuticals, Inc. operates as a defendant. Its single tracked case in the U.S. patent litigation database, Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al., shows the company as a defendant. This posture is consistent with an operating pharmaceutical company that faces patent challenges, often related to generic drug approvals.
The sole tracked case involving Lupin Pharmaceuticals, Inc. is Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al. in the U.S. District Court for the District of Delaware. This type of litigation is common in the pharmaceutical industry, frequently involving disputes over patents protecting branded drugs challenged by generic manufacturers. Lupin has a history of receiving FDA approvals for various medications and continues to expand its product offerings.
The District Court found Lupin did not infringe US Patent 8501730 and US Patent 8273735, with US Patent 8273735 also found invalid as obvious. On appeal, the Federal Circuit affirmed the non-infringement finding for 8501730, but controversially determined its asserted method claims were invalid as obvious.